Acute hepatitis C during the third trimester of pregnancy

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 5, 2006, Pages 786-789

  Gonzalez, Florent ^a   Medam Djomo, Michèle Ange ^a   Lucidarme, Damien ^a,b   Khalil, Ali ^a   Decoster, Anne ^a   De L'Aulnoit, Denis Houze ^a   Filoche, Bernard ^a  

^a Centre Hospitalier Saint Philibert GHICL   (France)

^b Service de Pathologie Digestive   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; DELIVERY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; GESTATIONAL AGE; HEPATITIS C; HUMAN; INFANCY; INFANT; JAUNDICE; PREMATURE LABOR; RELAPSE; RISK ASSESSMENT; SUBSTANCE ABUSE; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

EID: 33745501715     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73316-4     Document Type: Article

References (30)

1. Grangé JD, Antoine JM, Amiot X. Virus de l'hépatite C et grossesse. Gastroenterol Clin Biol 1999;23:1033-9.
2. Zuckerman MA, Aitken C, Whitby K, Deaville R, Sanders E, Glynn MJ, et al. Acute hepatitis C viral infection during pregnancy: failure of mother to infant transmission. J Med Virol 1997;52:161-3.
3. Suda T, Ohkoshi S, Aoyagi Y, Fujimaki T, Narisawa R, Nomoto M, et al. A pregnant case of severe acute hepatitis type C successfully treated with natural interferon-alpha and showing no evidence of a maternal transmission of HCV to the newborn. Acta Med Biol 1999;47:75-80.
4. Zambo MC, Lockwood DM. Hepatitis C seroconversion in pregnancy. Br J Obstet Gynaecol 1994;101:722-4.
5. Rimon E, Lurie Y, Bass DD, Levi S. Acute hepatitis C during pregnancy. Arch Gynecol Obstet 1998;262:95-7.
6. Navajas Leon FJ, Castillo Grau P, Hervias Cruz D, Martin Arranz MD, Segura Cabral JM. Hepatitis C aguda en paciente gestante. Gastroenterol Hepatol 2004;27:292-4.
7. Ozaslan E, Yilmaz R, Simsek H, Tatar G. Interferon therapy for acute hepatitis C during pregnancy. Ann Pharmacother 2002;36:1715-8.
8. Ghosn J, Pierre-François S, Thibault V, Duvivier C, Tubiana R, Simon A, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004;5:303-6.
9. Lucidarme D, Raabe JJ, Boruchowicz A, Nguyen-Khac E, Foutrein MC, Harbonnier J, et al. Traitement par l'interféron alpha 2a des hépatites virales aiguës C dans la population de toxicomanes injecteurs (res). Gastroenterol Clin Biol 2002;26:769.
10. Bacq Y. Hépathopathies au cours de la grossesse. Gastroenterol Clin Biol 2001;25:791-8.
11. Krawczynski K. Hépatite de type E. Hépatite non A-non B épidémique à transmission entérale. In: Benhamou JP, Bircher J, McIntyre N, Rizetto M, Rodes J, (eds). Hépatologie Clinique. Paris; Médecine-Sciences Flammarion, 1993:617-20.
12. Minkoff H. Prematurity: infection as an etiological factor. Obstet Gynecol 1983;62:137-44.
13. Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994;330:744-50.
14. Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccacco ML, et al. Mother-to-infant transmission of hepatitis C virus. Lancet 1995;435:289-91.
15. Tovo PA, Palomba E, Ferraris G, Principi N, Ruga E, Dallacasa P, et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Clin Infect Dis 1997;25:1121-4.
16. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8.
17. Grangé JD. Traitement de l'hépatite aiguë C. Gastroenterol Clin Biol 2002;26:832-7.
18. Vogel W, Graziadei I, Umlauf F, Datz C, Hackl F, Allinger S, et al. High-dose interferon alpha 2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996;41(Suppl):81S-5.
19. Wedemeyer H, Jäckel E, Wiegand J, Cornberg M, Manns MP. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. Hepatology 2004;39:1201-3.
20. Product information. Intron-A (interferon alpha-2b). Kenilworth, NJ: Shering, 2001.
21. Product information. Roferon-A (interferon alpha-2b). Nutley, NJ: Roche Pharmaceuticals, 2002.
22. Ferm VH, Willhite C, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978;17:93-101.
23. Pregnancy categories for prescription drugs. FDA Drug Bull 1982;12:24-5.
24. Nephew KP, McClure KE, Day ML, Xie S, Roberts RM, Pope WF. Effects of intramuscular administration of recombinanat bovine interferon-alpha during the period of maternal recognition of pregnancy. J Anim Sci 1990;68:2766-70.
25. Hegenbarth K, Maurer U, Kroisel PM, Ficker P, Trauner M, Stauber RE. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. Am J Gastroenterol 2001;96:2286-7.
26. Mishkin D, Deschenes M. Conception soon after discontinuiting interferon/ribavirin therapy: a successful outcome. Am J Gastroenterol 2001;96:2285.
27. Trotter JF, Zygmunt AJ. Conception and pregnancy during interferon alpha therapy for chronic hepatitis C. J Clin Gastroenterol 2001;32:72-8.
28. Placebo-controlled multicentre randomised trial of interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491-7.
29. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622-7.
30. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004;39:1721-31.